OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of neuroactive steroids for the treatment of postpartum depression
Handan Gunduz‐Bruce, Koji Takahashi, Ming‐Yi Huang
Journal of Neuroendocrinology (2021) Vol. 34, Iss. 2
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Prevalence and correlates of perinatal depression
Khalood Al‐abri, Dawn Edge, Christopher J. Armitage
Social Psychiatry and Psychiatric Epidemiology (2023) Vol. 58, Iss. 11, pp. 1581-1590
Open Access | Times Cited: 79

Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder
Andrew J. Cutler, Gregory W. Mattingly, Vladimir Maletic
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 63

Unveiling the prevalence and risk factors of early stage postpartum depression: a hybrid deep learning approach
Umesh Kumar Lilhore, Surjeet Dalal, Neetu Faujdar, et al.
Multimedia Tools and Applications (2024) Vol. 83, Iss. 26, pp. 68281-68315
Closed Access | Times Cited: 19

Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: A randomized controlled trial
Qingren Liu, Qian-Kun Zong, Lili Ding, et al.
Journal of Affective Disorders (2023) Vol. 339, pp. 815-822
Open Access | Times Cited: 40

Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy
Doodipala Samba Reddy, Robert H. Mbilinyi, Emily R. Estes
Psychopharmacology (2023) Vol. 240, Iss. 9, pp. 1841-1863
Open Access | Times Cited: 20

Zuranolone – synthetic neurosteroid in treatment of mental disorders: narrative review
Rafał Marecki, Joanna Kałuska, Agata Kolanek, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 13

The emergence of antidepressant drugs targeting GABAA receptors: A concise review
Xénia Gonda, Frank I. Tarazi, Péter Döme
Biochemical Pharmacology (2024) Vol. 228, pp. 116481-116481
Open Access | Times Cited: 4

Synthetic Approaches to the New Drugs Approved during 2023
Scott P. France, Erick A. Lindsey, Emma L. McInturff, et al.
Journal of Medicinal Chemistry (2025)
Closed Access

Pharmacological Monotherapy for Depressive Disorders: Current and Future, a Narrative Review
Keming Gao, Evrim Bayrak Oruc, Buket Koparal
Medicina (2025) Vol. 61, Iss. 4, pp. 558-558
Open Access

A method for predicting postpartum depression via an ensemble neural network model
Yangyang Lin, Dongqin Zhou
Frontiers in Public Health (2025) Vol. 13
Open Access

Inflammatory pathophysiological mechanisms implicated in postpartum depression
Jialei Zhu, Jing Jin, Jing Tang
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 18

The importance of translationally evaluating steroid hormone contributions to substance use
Erin E. Maher, Ashley M. Strzelecki, Jessica Weafer, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101059-101059
Open Access | Times Cited: 9

The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials
Jiao Zou, Ling Yang, Guoyu Yang, et al.
Psychiatry Research (2023) Vol. 328, pp. 115450-115450
Closed Access | Times Cited: 9

Efficacy and tolerability of zuranolone in patients with depression: a meta-analysis of randomized controlled trials
Youjia Qiu, Yuchen Tao, Aojie Duan, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 2

Factors promoting the release of picrotoxin from the trap in the GABA(A) receptor pore
Julia V. Bukanova, E. I. Solntseva, V. G. Skrebitsky
Neurochemistry International (2024) Vol. 175, pp. 105703-105703
Closed Access | Times Cited: 2

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 5, pp. 2949-2970
Open Access | Times Cited: 2

Neurotherapeutic Potential of Water-Soluble pH-Responsive Prodrugs of EIDD-036 in Traumatic Brain Injury
Russell G. Fritzemeier, Aletta E. van der Westhuyzen, Michael P. D’Erasmo, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 8, pp. 5397-5414
Closed Access | Times Cited: 6

Antidepressant effects of activation of infralimbic cortex via upregulation of BDNF and β-catenin in an estradiol withdrawal model
Jiali Chen, Yiying Zhou, Miaojun Lai, et al.
Psychopharmacology (2024) Vol. 241, Iss. 9, pp. 1923-1935
Open Access | Times Cited: 1

Understanding and treating postpartum depression: a narrative review
Vincenzo Cardaci, Matteo Carminati, Mattia Tondello, et al.
International Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 1

Identification of risk loci for postpartum depression in a genome‐wide association study
Xue Li, Nagahide Takahashi, Akira Narita, et al.
Psychiatry and Clinical Neurosciences (2024)
Open Access | Times Cited: 1

Enhancing GABA inhibition is the next generation of medications for essential tremor
William G. Ondo
International review of neurobiology (2022), pp. 317-334
Closed Access | Times Cited: 7

Page 1 - Next Page

Scroll to top